[Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Sabate, M., Jimenez-Quevedo, P., Macaya, C. (2005). Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes,54 (8), 2430–2435.10.2337/diabetes.54.8.243016046311]Search in Google Scholar
[Badimon, L., Padró, T., Vilahur, G. (2012). Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care, 1 (1), 60–74.10.1177/2048872612441582376054624062891]Search in Google Scholar
[Balucani, C., Barlinn, K., Zivanovic, Z., Parnetti, L., Silvestrini, M., Alexandrov, A. V. (2010). Dual antiplatelet therapy in secondary prevention of ischemic stroke: A ghost from the past or a new frontier? Stroke Res. Treat., DOI 2010:427418.]Search in Google Scholar
[Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., et al. (2001). Cyclooxygenase inhibitors and the antiplateleteffects of aspirin. New Engl. J. Med.,345, 1809–1817.10.1056/NEJMoa00319911752357]Search in Google Scholar
[Feher, G., Feher, A., Pusch, G., et al. (2010). Clinical importance of aspirin and clopidogrel resistance. World J. Cardiol., 2 (7), 171–186.10.4330/wjc.v2.i7.171299891621160749]Search in Google Scholar
[Feher, G., Feher, A., Pusch, G., Lupkovics, G., Szapary, L., Papp, E. (2009). The genetics of antiplatelet drug resistance. Clin. Genet.,75 (1), 1–18.10.1111/j.1399-0004.2008.01105.x19067731]Search in Google Scholar
[Ferreira, I. A., Mocking, A. I., Feijge, M. A., et al. (2006). Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol.,26, 417–422.10.1161/01.ATV.0000199519.37089.a016339499]Search in Google Scholar
[Fiolaki, A., Katsanos, A. H., Kyritsis, A. P., Papadaki, S., Kosmidou, M., Moschonas, I. C. Giannopoulos, S. (2017). High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. J. Neurol. Sci., 376, 112–116.10.1016/j.jns.2017.03.01028431593]Search in Google Scholar
[Freedman, J. E., Hylek, E. M. (2009). Clopidogrel, genetics, and drug responsiveness. New Engl. J. Med.,360 (4), 411–413.10.1056/NEJMe081051319164193]Search in Google Scholar
[Goodman, T., Ferro, A., Sharma, P. (2008). Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Brit. J. Clin. Pharmacol., 66 (2), 222–232.10.1111/j.1365-2125.2008.03183.x249291318429969]Search in Google Scholar
[Gurbel, P. A., Tantry, U. S. (2007). Clopidogrel resistance? Thrombosis Res., 120 (3), 311–321.]Search in Google Scholar
[Karepov, V., Tolpina, G., Kuliczkowski, W., Serebruany, V. (2008). Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovas. Dis., 26 (3), 272–276.10.1159/00014745518648200]Search in Google Scholar
[Krasopoulos, G., Brister, S. J., Beattie,W. S., Buchanan, M. R. (2008). Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ,336, 195–198.10.1136/bmj.39430.529549.BE]Search in Google Scholar
[Mansour, K., Taher, A. T., Musallam, K. M., Alam, S. (2009). Aspirin resistance. Adv. Hematol. 10.1155/2009/937352. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19960045 (accessed 15.05.2019).]Search in Google Scholar
[Motovská, Z., Varvarovský, I., Ostádal, P. (2017). ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa, 59 (6), e592–e612.]Search in Google Scholar
[Poulsen, T. S., Jorgensen, B., Korsholm, L., et al. (2017). Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb. Res.,119, 555–562.]Search in Google Scholar
[Jones, R., Arps, K., Davis, D. M., Blumenthal, R., Martin, S. S. (2018). Clinician Guide to the ABCs of Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Available from: https://www.acc.org/latest-in-cardiology/articles/2018/03/30/18/34/clinician-guide-to-the-abcs (accessed 15.05.2019).]Search in Google Scholar
[Simon, T., Verstuyft, C., Mary-Krause, M., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. New Engl. J. Med.,360 (4), 363–375.10.1056/NEJMoa0808227]Search in Google Scholar
[Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G., Jukema, J. W., Huisman, M. V. (2007). Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Amer. Heart J., 154, 221–231.10.1016/j.ahj.2007.04.014]Search in Google Scholar
[Wang, C. B., Hu, D. Y., Shi, X. B., et al. (2006). Aspirin resistance in patients taking small dose of aspirin. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 18, 219–223.]Search in Google Scholar
[Wang, T. H., Bhatt, D. L., Topol, E. J. (2005). Aspirin and clopidogrel resistance: An emerging clinical entity. Eur. Heart J., 27 (6), 647–654.]Search in Google Scholar
[Weber, A. A., Zimmerman, K. C., Meyer-Kirchrath, J, Schor, K. (1999). Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet,353, 900.10.1016/S0140-6736(99)00498-5]Search in Google Scholar
[Wong, K. S. L., Wang, Y., Leng, X., Mao, C., Tang, J., Bath, P. M. W., Wang, Y. (2013). Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. Circulation, 128 (15), 1656–1666.10.1161/CIRCULATIONAHA.113.00318724030500]Search in Google Scholar
[Zimmermann, N., Wenk, A., Kim, U., Kienzle, P., Weber, A.-A., Gams, E., Schror, K., Hohlfeld, T. (2003). Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation,108, 542–547.10.1161/01.CIR.0000081770.51929.5A12874188]Search in Google Scholar